ClinicalTrials.gg
RecruitingNCT06539689SURFUpdated Aug 6, 2024

A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries

An interventional study of Sperstent® peripheral spot stent system and Everflex® self-expanding peripheral stent system in Peripheral Arterial Disease, Stenosis and Dissection, sponsored by FrontAce Scientific Co., Ltd. Recruiting at 12 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by FrontAce Scientific Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.

Planned enrollment
13th of 53
240 · median 167
Started
2024
with 5 others
No phase
34 of 80
13 open now
Primary completion
2026-12
later than 16 of 33 live
Registered
63rd of 80
by date

Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 13th largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2024, is one of 34 with no phase, reaches primary completion later than 16 of the 33 other live ones, and was the 63rd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Peripheral Arterial Disease with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular treatment of post-balloon angioplasty (post-PTA) residual lesions including stenoses and/or dissections in femoral and proximal popliteal arteries.

03

Conditions studied

  • Peripheral Arterial Disease
  • Stenosis
  • Dissection

Keywords

  • Peripheral Arterial Disease
  • Spot stent
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-85 years old, male or female;
  • The target lesion is located in the superficial femoral artery or the proximal popliteal artery;
  • Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5;
  • Estimated >1 year;
  • Subject has been informed of and understands the nature of the study and provides signed to participate in the study.

Angiographic Inclusion Criteria:

  • Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate);
  • Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions);
  • After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and/or presence of at least one post-PTA dissection (Type A-F) (by visual estimate);
  • Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%;
  • Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention).

Exclusion criteria

Exclusion Criteria:

  • Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis;
  • Patients with serum creatinine >2.5mg/dl during screening or undergoing long-term hemodialysis or peritoneal dialysis;
  • Severe coagulation disorder;
  • Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery);
  • A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding);
  • Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment;
  • Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus;
  • Systemic infection or uncontrolled infection within the target limb;
  • Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics;
  • Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year;
  • Patients who are planning to have major lower limb amputations on the target side of the lesion;
  • Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery;
  • Participating in clinical trials of other medical devices or drugs;
  • The investigator considers the patient is not suitable for participation in the clinical trial.

Angiographic Exclusion Criteria:

  • Failure of the guidewire to pass through the lesion;
  • During the procedure, the target lesions had received or were scheduled to receive volume reduction procedures such as cryogenic angioplasty, laser angioplasty, and percutaneous intracavity plaque gyrotomy;
  • The target lesion before stent implantation is thrombotic obliteration, which is not suitable for stent implantation;
  • The target lesions were severely calcified and could not fully predilate; Or grade 4 calcification;
  • Acute vascular occlusion or acute or subacute thrombosis in the target lesion;
  • Stent was implanted into the target vessel before enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Sperstent® peripheral spot stent system

    subjects using the Sperstent® peripheral spot stent system

    Device: Sperstent® peripheral spot stent system

  • Active comparator
    Everflex® self-expanding peripheral stent system

    subjects using the Everflex® self-expanding peripheral stent system

    Device: Everflex® self-expanding peripheral stent system

Interventions

  • DeviceSperstent® peripheral spot stent system

    Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography(DSA)

  • DeviceEverflex® self-expanding peripheral stent system

    Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography(DSA)

06

What researchers measure

Primary outcomes

  1. Primary Patency

    Primary patency defined as freedom from clinically driven target lesion revascularization (CD-TLR) and freedom from duplex ultrasound derived binary restenosis at 12 months post-operation.(defined as PSVR \>2.5)

    Time frame: 12 months post-operation

  2. Freedom from Major Adverse Events (MAEs)

    Freedom from the occurrence of any new-onset MAEs defined as all-cause death, index limb amputation (above the ankle), or clinically-driven target lesion revascularization (CD-TLR) at 30 days post-operation.

    Time frame: 30 days post-operation

Secondary outcomes

  1. Rate of Device Success

    Defined as successful delivery, release and retrieval of the device.

    Time frame: immediately post-operation

  2. Rate of Procedural Success

    Demonstrated vessel patency (\<30% residual DS, by visual estimate) without the use of a bailout stent or the occurrence of MAE upon completion of the index procedure.

    Time frame: immediately post-operation

  3. Primary Patency at 30 days and 6 months

    defined as freedom from clinically driven target lesion revascularization (CD-TLR) and freedom from duplex ultrasound derived binary restenosis at 30 days and 6 months post-operation (defined as PSVR \>2.5)

    Time frame: 30 days and 6 months post-operation

  4. Rate of clinically driven target lesion revascularization (CD-TLR)

    Clinically driven target lesion revascularization (CD-TLR) was defined as an endovascular reintervention performed for a \>50% diameter stenosis of the target vessel in the presence of a recurrent PAD symptom after the initial endovascular procedure.

    Time frame: 30 days, 6 months and 12 months post-operation

  5. Changes from Baseline in Rutherford Classification

    Defined as change in target limb Rutherford class from baseline. Rutherford Classification is defined as follows, with increasing severity: Rutherford Category 0 - Asymptomatic. Rutherford Category 1 - Mild Claudication. Rutherford Category 2 - Moderate Claudication. Rutherford Category 3 - Severe Claudication. Rutherford Category 4 - Ischemic Rest Pain. Rutherford Category 5 - Minor Tissue Loss (minor exertion). Rutherford Category 6 - Major Tissue Loss (gangrene).

    Time frame: 30 days, 6 months and 12 months post-operation

  6. Changes from Baseline in Ankle-brachial Index (ABI)

    Defined as change of target limb ABI from baseline. The Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm.

    Time frame: 30 days, 6 months and 12 months post-operation

  7. Duplex Ultrasound (DUS) Derived Lesion Patency

    Lesion Patency is evaluated by Duplex Ultrasound (DUS)

    Time frame: 30 days, 6 months and 12 months post-operation

  8. Rate of major adverse event(s) (MAEs)

    MAEs defined as all-cause death, index limb amputation (above the ankle), or clinically-driven target lesion revascularization (CD-TLR) .

    Time frame: 6 months and 12 months post-operation

  9. Rate of Stent Fracture

    Stent fractures will be analyzed by X-ray at 12 months post-operation. The stents implanted into a certain subject will be analyzed collectively in the assessment. Stent fractures will be assessed with Grade I, II, III or IV as follow. Grade I - a single strut fracture only. Grade II - multiple single strut fractures that occur at different sites of a stent or different stents. Grade III - multiple nitinol stent fractures resulting in complete transverse linear fracture. Grade IV - a spiral dissection of a stent. Fractures of Grade I are least severe, increasing in severity to Grade IV.

    Time frame: 12 months post-operation

07

Study locations

3 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 30 months is close to that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 6, 2024
StartActual
Jun 4, 2024
Primary completionEst.
Dec 4, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06539689
Lead sponsor
FrontAce Scientific Co., Ltd
Responsible party
Sponsor
First posted
Aug 6, 2024
Start date
Jun 4, 2024
Primary completion
Dec 4, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 6, 2024

Study contacts

Min Zhou, Dr.
Contact
zhouminnju@126.com
01186-25-83106666 ext. 60770
Xiang Wang, Dr.
Contact
vascular_doc@qq.com
01186-21-38804518 ext. 22265

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion